MACULAR PERFUSION DETERMINED BY FUNDUS FLUORESCEIN ANGIOGRAPHY AT THE 4-MONTH TIME POINT IN A PROSPECTIVE RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB OR LASER THERAPY IN THE MANAGEMENT OF DIABETIC MACULAR EDEMA (BOLT STUDY)

The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The Twenty-five-Year Incidence of Macular Edema in Persons with Type 1 Diabetes

(2009) Ronald Klein et al.   OPHTHALMOLOGY

Effects of Macular Ischemia on the Outcome of Intravitreal Bevacizumab Therapy for Diabetic Macular Edema

(2009) Eun Jee Chung et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Diabetic Macular Edema: Pathogenesis and Treatment

(2009) Neelakshi Bhagat et al.   SURVEY OF OPHTHALMOLOGY

Clinically Significant Macular Edema and Survival in Type 1 and Type 2 Diabetes

(2008) Flavio E. Hirai et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy

(2008) Louis S Matza et al.   Health and Quality of Life Outcomes

SURVEILLANCE FOR POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE USE OF INTRAVITREAL BEVACIZUMAB FOR RETINAL AND CHOROIDAL VASCULAR DISEASE

(2008) LISA J. WONG et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA

(2008) DANIEL KOOK et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES